GPT-5 lowers the cost of cell-free protein synthesis

OpenAI's GPT-5 artificial intelligence combined with Ginkgo Bioworks' cloud automation technology has successfully reduced cell-free protein synthesis costs by 40% through closed-loop experimentation in recent laboratory breakthroughs. This innovative autonomous lab represents a significant advancement in biotechnology research by leveraging artificial intelligence to optimize protein production processes without the need for living cells. The closed-loop experimentation system allows the AI to design experiments, analyze results, and automatically adjust parameters, creating a self-improving research environment that continuously refines protein synthesis protocols. The breakthrough comes as the biotechnology industry increasingly seeks to reduce production costs while increasing efficiency in protein manufacturing applications ranging from therapeutics to industrial enzymes. By eliminating the need for cell culture and significantly reducing manual intervention, this technology promises to accelerate research timelines and make protein-based therapies more accessible and affordable for medical treatments and industrial applications.